Australia based Commonwealth Scientific and Industrial Research Organization (CSIRO) says that it has started working with local biotechnology and pharmaceutical companies to improve existing psychedelics products and develop new ones.
CSIRO will be joining hands with the local biotech companies to extract, synthesize, improve and develop manufacturing processes for up to 15 different psychedelics compounds. Some researcher in Australia and across the world have been testing psychedelics components such as MDMA, psilocybin and others in strictly controlled clinical setting to find out if they can be an effective treatments for mental health related illnesses.
“CSIRO is well-placed to contribute to this emerging area of research, which could lead to life-changing advancements in mental health. Clinical trials both here and internationally have been using known psychedelics, usually MDMA or psilocybin with impressive results but there’s still much to be learnt about how these drugs work and how improvements to their chemical composition could enhance patient outcomes. By working with local industry to improve drug design and the patient experience, CSIRO can push Australia into a leadership position in the development of these potentially life-changing medications,” said CSIRO scientist Adjunct Professor, Peter Duggan.
It is estimated that one out of every five people in Australia will suffer from one from of mental illness every year some studies further suggest that more than 33% of mental health patients may not respond to existing treatments.